From GlobeNewswire: 2025-05-09 02:00:00

The global Periodontal Therapeutics Market was valued at USD 859.13 million in 2023, set to reach USD 1666.11 million by 2032, growing at a 7.62% CAGR. Increasing cases of chronic periodontal diseases and advancements in drug delivery technologies are driving market expansion.

In the U.S., the market reached USD 246.62 million in 2023 and is projected to hit USD 451.30 million by 2032. High public health spending and early screening programs contribute to early diagnosis and treatment, making the U.S. a key market driver.

Growth in the periodontal therapies market is fueled by rising global incidence of periodontal diseases, particularly in ageing populations. Advances in drug delivery and easy access to medications are driving market expansion.

In the U.S., awareness campaigns and reimbursement support have led to higher rates of diagnosis and interventions. Cooperation between research institutes and pharmaceutical companies has resulted in the development of novel medications targeting specific bacterial species causing gum disease.

Major companies in the Periodontal Therapeutics market include 3M, Colgate-Palmolive, GlaxoSmithKline, Pfizer, Johnson & Johnson, and more. These companies offer a range of products for gum disease treatment, contributing to market growth.

In 2023, chronic periodontal disease held a 35.16% market share, driven by its chronic nature requiring continuous treatment. Gingivitis is expected to expand due to better oral care practices and early treatment availability.

Doxycycline led the market with a 38.19% share in 2023, known for reducing periodontal pocket depth and stopping tissue damage. Locally administered antimicrobials are the fastest-growing category, with targeted action and reduced side effects driving demand.

Hospital pharmacies held the highest market share in 2023 at 43.10%, offering prescription-based treatments. Retail pharmacies are the fastest-growing channel, driven by customer convenience and access to prescription-strength medications. Retail stores are enhancing credibility with oral health counseling by chemists and collaboration with dentists. The global periodontal therapeutics market is segmented by type, drug type, and distribution channel, with North America leading in 2023. Asia-Pacific is expected to see rapid growth due to increased access to healthcare and awareness of oral health. Recent developments include new dental care pathways and advanced gum disease treatments.

In September 2024, Haleon and NIHR introduced a new dental care pathway to screen for Type 2 diabetes during dental checkups. Colgate-Palmolive launched “PerioGard Advanced Care” gel for gingivitis, and Sunstar Group introduced a localized drug delivery system for periodontal pockets. The market analysis and outlook report for 2024-2032 offers insights into periodontal therapeutics trends and statistics.

SNS Insider provides market research and consulting globally, offering clients the knowledge needed to navigate changing circumstances. Through surveys, video talks, and focus groups, we provide current market data, consumer insights, and opinions for confident decision-making. Explore related reports on the oral care market, dental regeneration, pet dental health, digital dentistry, and dental biomaterials.



Read more at GlobeNewswire: Periodontal Therapeutics Market to Hit USD 1666.11 Million